Back to all bills
Standard Summary
Comprehensive overview in 1-2 paragraphs
The SAFE Act (Save Americans from the Fentanyl Emergency Act) would significantly tighten federal control over fentanyl-related substances (FRS) by placing them under strict scheduling and enhanced penalties, while also creating new pathways to facilitate legitimate research and potential future reclassification. Key changes include defining and broadly classifying fentanyl-related substances as Schedule I unless exempted or rescheduled, establishing specific gravity-based penalties for fentanyl and its analogues, and creating a formal process for removing or re-scheduling FRS if evidence shows a lower abuse potential. The bill also expands research registration rules to streamline legitimate Schedule I research, adds protections and procedures for multiple research sites, and requires a GAO report within four years assessing the impact of class scheduling on FRS proliferation, enforcement, and related issues. In addition, the bill introduces the possibility to vacate or reduce sentences for past convictions involving substances that were later removed from Schedule I, and it imposes new rules and transparency around special research procedures and interim rulemaking. Overall, the bill aims to curb the rapid emergence of new fentanyl-related substances by hardening scheduling and penalties, while balancing research needs and potential reclassification pathways based on scientific evaluations.
Key Points
- 1Broad scheduling of fentanyl-related substances
- 2- Adds a comprehensive definition of fentanyl-related substances (FRS) and places them in Schedule I, with limited exemptions, unless the substance is specifically exempted or listed in another schedule.
- 3- Requires the Attorney General to publish a Federal Register list of individual FRS within 60 days of determining they meet the definition; absence from the list does not remove control status if criteria are met.
- 4- Provides a pathway to remove or reschedule an FRS based on scientific and medical evaluations, potentially moving it to a lower schedule (including Schedule III) if abuse potential is lower than Schedule I/II substances.
- 5Penalty provisions for fentanyl-related substances
- 6- Domestic offenses: changes thresholds for fentanyl and its analogues in 21 U.S.C. 841(b)(1) to set specific gram-based penalties (e.g., 400 grams+ of fentanyl mixture; 100 grams+ of an analogue treated as Schedule I or II) and similar adjustments for other subparagraphs, while explicitly barring quantity-based mandatory minimum penalties for FRS.
- 7- Import/export offenses: mirrors the domestic penalties, with specific grams thresholds for fentanyl and analogues for the Drug Import/Export regime (21 U.S.C. 960(b)).
- 8- Adds FRS (as defined in Schedule I(e) of Section 202(c)) to the list of substances for which the penalty framework applies and clarifies that penalties apply to fentanyl-related substances as defined in Schedule I.
- 9- Section 3 also expands penalties to include fentanyl-related substances in applicable sections and ensures FRS are treated as part of the relevant controlled substance schedules.
- 10Removal and reclassification of FRS
- 11- Adds a new Section 201(k) outlining a formal process for determining whether an FRS should be removed from Schedule I or rescheduled, driven by scientific and medical evaluations.
- 12- If removal is determined: AG must issue an order within 90 days after the Secretary’s evaluation; if rescheduling to Schedule III is determined, the same 90-day timeline applies.
- 13- Establishes evaluation factors, including pharmacological evidence and other CSA criteria, and requires advance notice to the AG before sending evaluations.
- 14- Provides a process for petitions to remove or reclassify an FRS and ensures ongoing control can be adjusted under other CSA provisions.
- 15Past cases and potential sentence adjustments
- 16- Adds potential relief for defendants previously convicted under offenses involving an FRS that has since been removed from Schedule I or moved to another schedule, allowing vacating or reducing sentences to reflect the updated scheduling, on a case-by-case basis.
- 17Research and registration reforms
- 18- Creates an alternative registration pathway for Schedule I research (Section 303(m)) to streamline research with Schedule I substances, including both researchers already registered for Schedule I/II substances and new applicants.
- 19- Allows a single registration for related research sites at a single institution when sites are within the same city/county under control of the same organization, with required site notifications and regulatory oversight.
- 20- Expands the ability to conduct certain manufacturing activities that are “coincident to research” without a separate manufacturing registration, subject to stated limits and disclosures, while expressly excluding marihuana from those manufacturing allowances.
- 21- Improves transparency for “special procedures” by requiring public posting of processes and criteria used to handle certain Schedule I research applications, and sets a timeline for posting.
- 22Administrative rulemaking and oversight
- 23- Requires the Attorney General to issue interim final rules within one year of enactment, with interim rules effective immediately but open for public comment; final rules to follow under standard rulemaking procedures.
- 24- Directs a GAO review within four years to analyze the implementation and impact of permanent class scheduling for FRS, including effects on research, enforcement, sentencing, and the broader goals of reducing proliferation.
- 25Implementation and regulatory alignment
- 26- Ensures that new procedures and scheduling do not override treaty obligations when applicable, preserving international commitments where relevant.
- 27- Provides additional duty to notify and share substance identity and basis for FRS determinations with the Secretary of Health and Human Services and other federal partners.
Impact Areas
Primary group/area affected- Federal and state law enforcement, prosecutors, and courts handling fentanyl-related substance cases.- Individuals and organizations involved with fentanyl-related substances, including manufacturers, distributors, and users.- Researchers and institutions conducting legitimate research involving Schedule I substances, who gain new streamlined pathways and oversight for Schedule I research.Secondary group/area affected- The pharmaceutical and chemical industries adapting to stricter scheduling and potential reclassification processes for fentanyl-related substances.- Public health and medical communities, which may see changes in enforcement, scheduling, and research regulatory environments.- International treaty compliance and federal regulatory coordination related to controlled substances.Additional impacts- Potential changes in sentencing dynamics due to new removal/rescheduling provisions and past-case relief, which could alter incentives and enforcement outcomes.- The GAO review could influence future policy decisions about class scheduling and the regulation of fentanyl-related substances.- Interim regulatory changes could affect how quickly new FRS are controlled and how research timelines align with enforcement actions.
Generated by gpt-5-nano on Nov 19, 2025